Co-Diagnostics

Co-Diagnostics Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Co-Diagnostics (CODX) as of Nov 20, 2026 is -1,453.96. In the previous year, Cash Conversion Cycle (CCC) was -799.21 — a change of 81.93% (lower).

Cash Conversion Cycle

-1,453.96

YoY

81.93%

Last updated:

Cash Conversion Cycle (CCC) of Co-Diagnostics is 2025 -1,453.96 . Cash Conversion Cycle (CCC) of Co-Diagnostics was 2024 -799.21 . It decreases by 81.93% lower compared to the previous year.

The Co-Diagnostics Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2018
-5,084.35 USD
Jan 1, 2019
790.54 USD
Jan 1, 2020
221.97 USD
Jan 1, 2021
121.60 USD
Jan 1, 2022
327.56 USD
Jan 1, 2023
32.21 USD
Jan 1, 2024
-799.21 USD
Jan 1, 2025
-1,453.96 USD
The Co-Diagnostics Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-1,453.96+81.93%
-799.21-2,581.18%
32.21-90.17%
327.56+169.37%
121.60-45.22%
221.97-71.92%
790.54-115.55%
-5,084.35-86.75%
-38,374.55+3,656.31%
-1,021.60+22.14%
-836.41—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Co-Diagnostics Stock analysis

What does Co-Diagnostics do? Co-Diagnostics, Inc. develops and sells diagnostic tests using proprietary reagents and a test design system for diseases and pathogens including tuberculosis, drug-resistant tuberculosis, hepatitis B and C, malaria, dengue, HIV, and Zika virus. The company also markets self-contained lab systems (MDx devices) from other manufacturers. Its products are sold to laboratories and healthcare providers for molecular testing of organisms and genetic diseases, automating complex procedures in test development and administration. The firm generates revenue through the sale of diagnostic reagents, validated tests, and MDx devices. The company's diagnostic technology focuses on nucleic acid detection and analysis, enabling molecular testing for various pathogens and genetic conditions. Its proprietary system allows for the design and validation of tests in-house, which are then marketed to healthcare institutions. Revenue streams include reagent sales, test kits, and equipment from partner manufacturers. Co-Diagnostics, Inc. targets laboratories and healthcare providers as key customers for its diagnostic solutions. The firm's products are designed to streamline molecular testing processes, reducing the complexity of traditional methods. This approach supports the company's revenue model based on direct sales of its proprietary tests and complementary equipment. Co-Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Co-Diagnostics stock

Cash Conversion Cycle (CCC) of Co-Diagnostics is -1,453.96 in 2025.

Cash Conversion Cycle (CCC) of Co-Diagnostics changed from -799.21 to -1,453.96, representing a 81.93% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Co-Diagnostics since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Co-Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Co-Diagnostics

All Key Metrics — Co-Diagnostics